HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
Further expands HeartSciences extensive patent portfolio
進一步擴大HeartSciences廣泛的專利組合
Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that intellectual property (IP) exclusively licensed to HeartSciences has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for the detection of left ventricular (LV) and/or right ventricular (RV) dysfunction using deep learning, further strengthening the Company's AI-ECG IP portfolio.
2024年7月11日,得克薩斯州Southlake(GLOBE NEWSWIRE) - 醫心科技有限公司,註冊商號爲Heart Test Laboratories, Inc.,證券代碼爲納斯達克: HSCS;HSCSW,又稱HeartSciences(下稱“本公司”)是一家以人工智能爲核心的醫療科技公司,專注於通過對心臟疾病的早期檢測來挽救生命,致力於將ECG(又稱爲EKG)變得更加有臨床價值。每週有數百萬份ECG檢查,該公司的宗旨是通過使其成爲更有價值的心臟篩查工具,特別是在前線或臨床現場,改善醫療保健。HeartSciences擁有最大的人工智能-ECG算法庫之一,正在開發可在硬體無關的基於雲的平台上或其專有的MyoVista wavECG設備上提供的AI-ECG解決方案,以幫助全球各種醫療機構在合適的環境下診斷心血管疾病。HeartSciences的FDA覈准申請的第一項產品候選人MyoVista wavECG(簡稱MyoVista)是一項靜息狀態的12導聯心電圖,也旨在提供傳統的心電圖信息,並在同一檢查中提供與心臟功能障礙相關的診斷信息,這在傳統上只能通過使用心臟成像技術獲得。d/b/a HeartSciences (納斯達克:HSCS; HSCSW)("HeartSciences"或"公司"),一個專注於通過早期心臟疾病的檢測轉變ECGs/EKGs以拯救生命的人工智能(AI)爲基礎的醫療技術公司,今天宣佈,HeartSciences專有授權的知識產權(IP)已收到來自美國專利和商標局(USPTO)關於使用深度學習檢測左室(LV)和/或右室(RV)功能障礙的通知,進一步加強了公司的AI-ECG IP組合。
Heart failure (HF) is a growing worldwide public health issue affecting 64 million people annually1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system. Low-cost testing for heart failure has not been readily available for front-line physicians. With the development of AI-ECG algorithms, HeartSciences improves the early identification of patients that need additional testing, allowing earlier treatment and improved patient outcomes.
心力衰竭(HF)是全球範圍內影響6400萬人的公共衛生問題,與高死亡率、較低生活質量和降低身體能力以及對醫療保健體系產生巨大成本有關。對於心力衰竭的低成本測試一直不容易得到臨床一線醫生的使用。隨着AI-ECG算法的發展,HeartSciences改善了病人早期篩查的方法,允許更早的治療和改善患者的結局。
Andrew Simpson, Chief Executive Officer of HeartSciences, stated, "This patent allowance further expands our extensive AI-ECG IP portfolio. AI-ECG is set to change the detection of heart disease and this latest patent further bolsters value to HeartSciences and our stakeholders."
HeartSciences首席執行官Andrew Simpson表示: "這項專利授權進一步擴大了我們廣泛的AI-ECG IP組合。AI-ECG將改變心臟疾病的檢測,而這項最新的專利授權進一步增強了對HeartSciences和我們的利益相關者的價值。"
1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–1858.
1.《全球疾病和傷害發病率和流行病學研究2017》合作者。全球、區域和195個國家和地區的354種疾病和傷害的發病率、流行病學和年傷殘人數,1990-2017: 全球疾病負擔研究2017的系統分析。《柳葉刀》,2018年;392:1789–1858。
About HeartSciences
關於醫心科技公司
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test.
Heart Test Laboratories,Inc. d/b/a HeartSciences是一家醫療技術公司,旨在將創新的基於人工智能的技術應用於ECG(也稱爲EKG),以擴大和改善ECG的臨床效用。每週進行數百萬次心電圖檢查,公司的目標是通過使其成爲一種更有價值的心臟篩查工具,特別是在臨床一線或護理現場,來改善醫療保健。HeartSciences擁有最大的AI-ECG算法庫之一,並正在開發AI-ECG解決方案,可在硬件不可知雲平台或其專有的MyoVista wavECG設備上提供,以幫助在全球任何護理現場識別心血管疾病並以最適合不同護理提供者的方式進行處理。HeartSciences的FDA認證的第一個產品候選者,MyoVista wavECG或MyoVista,是一種靜息狀態的12導聯心電圖,也被設計爲提供與傳統的心臟成像疾病診斷相關的診斷信息。 MyoVista還提供相同測試的傳統ECG信息。
For more information, please visit: . X: @HeartSciences
更多信息,請訪問:@HeartSciences X。
Safe Harbor Statement
Safe Harbor聲明
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024, filed with the SEC on March 14, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
此公告包含根據1933年修改的證券法第27(A)節和1934年修改的證券交易法第21(E)節的前瞻性聲明。這些前瞻性聲明是根據1995年私人證券訴訟改革法案的"安全港"規定作出的,並涉及公司未來的財務和營運表現。除歷史事實陳述外,本文所載內容包括但不限於有關HeartSciences信仰和期望的聲明。這些聲明基於當前的期望、假設和涉及關於未來經濟、競爭和市場狀況以及未來經營決策的判斷等方面的不確定性,所有這些都難以或不可能準確預測,並且其中許多都不在公司的控制之內。這些前瞻性聲明中反映的期望涉及重大的假設、風險和不確定性,而這些期望可能被證明是不正確的。投資者不應過度依賴這些前瞻性聲明,這些聲明僅在本新聞稿發佈之日有效。潛在的風險和不確定性包括但不限於,HeartSciences2013財年報告文件Form 10-k中討論的風險,該文件於2018年6月18日提交給美國證券交易委員會(SEC)。HeartSciences2013財年第三季度報告文件Form 10-Q,於2018年3月14日提交給SEC。以及HeartSciences在www.sec.gov提交的其他文件。除證券法規定的向證券法律規定的部門報告之外,公司不承擔更新這些前瞻性聲明的義務。
Contacts:
聯繫人:
HeartSciences
Gene Gephart
+1-682-244-2578 (US)
info@heartsciences.com
HeartSciences
Gene Gephart
+1-682-244-2578(美國)
info@heartsciences.com
Investors:
投資者:
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com
吉爾馬汀集團
Vivian Cervantes
investorrelations@heartsciences.com